MA38637A1 - Benzoxazoles substitués - Google Patents

Benzoxazoles substitués

Info

Publication number
MA38637A1
MA38637A1 MA38637A MA38637A MA38637A1 MA 38637 A1 MA38637 A1 MA 38637A1 MA 38637 A MA38637 A MA 38637A MA 38637 A MA38637 A MA 38637A MA 38637 A1 MA38637 A1 MA 38637A1
Authority
MA
Morocco
Prior art keywords
substituted benzoxazoles
diseases
formula
benzoxazoles
substituted
Prior art date
Application number
MA38637A
Other languages
English (en)
Other versions
MA38637B1 (fr
Inventor
Philip Lienau
Adrian Tersteegen
Susanne Röhrig
Alexander Hillisch
Julia Strassburger
Stefan Heitmeier
Martina Victoria Schmidt
Anja Buchmüller
Christoph Gerdes
Tom Kinzel
Swen Allerheiligen
Karen Engel
Kersten Matthias Gericke
Michael Gerisch
Bernd Riedl
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38637A1 publication Critical patent/MA38637A1/fr
Publication of MA38637B1 publication Critical patent/MA38637B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des benzoxazoles substitués de formule (i) dans laquelle r1 représente un groupe de formule (ii), (iii), (iv), (v), ainsi que des procédés permettant de les produire, et leur utilisation dans la fabrication de médicaments destinés à traiter et/ou à prévenir des maladies, notamment des maladies cardio-vasculaires, de préférence des maladies thrombotiques ou thromboemboliques.
MA38637A 2013-06-03 2014-05-30 Benzoxazoles substitués MA38637B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170208 2013-06-03
PCT/EP2014/061229 WO2014195231A1 (fr) 2013-06-03 2014-05-30 Benzoxazoles substitués

Publications (2)

Publication Number Publication Date
MA38637A1 true MA38637A1 (fr) 2017-05-31
MA38637B1 MA38637B1 (fr) 2018-04-30

Family

ID=48534286

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38637A MA38637B1 (fr) 2013-06-03 2014-05-30 Benzoxazoles substitués

Country Status (27)

Country Link
US (1) US9493472B2 (fr)
EP (1) EP3004084B1 (fr)
JP (1) JP2016520111A (fr)
KR (1) KR20160016815A (fr)
CN (1) CN105408327A (fr)
AP (1) AP2015008896A0 (fr)
AR (1) AR096516A1 (fr)
AU (1) AU2014277072A1 (fr)
BR (1) BR112015029579A2 (fr)
CA (1) CA2913960A1 (fr)
CL (1) CL2015003476A1 (fr)
CR (1) CR20150631A (fr)
CU (1) CU20150164A7 (fr)
DO (1) DOP2015000290A (fr)
EA (1) EA201501176A1 (fr)
ES (1) ES2624996T3 (fr)
HK (1) HK1222649A1 (fr)
IL (1) IL242794A0 (fr)
MA (1) MA38637B1 (fr)
MX (1) MX2015016386A (fr)
NI (1) NI201500168A (fr)
PE (1) PE20160092A1 (fr)
PH (1) PH12015502650A1 (fr)
TN (1) TN2015000523A1 (fr)
TW (1) TW201536776A (fr)
UY (1) UY35592A (fr)
WO (1) WO2014195231A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016087322A1 (fr) * 2014-12-01 2016-06-09 Bayer Pharma Aktiengesellschaft Formes galéniques pharmaceutiques solides administrables par voie orale, à libération rapide de principe actif

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US20030225131A1 (en) 2002-04-05 2003-12-04 Burgey Christopher S. Thrombin inhibitors
MXPA05011223A (es) 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
AU2006262425C1 (en) 2005-06-23 2012-06-21 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
DE102006027163A1 (de) 2006-06-08 2007-12-13 Bayer Healthcare Ag Substituierte Benzoxazole

Also Published As

Publication number Publication date
DOP2015000290A (es) 2016-01-15
EP3004084B1 (fr) 2017-03-01
HK1222649A1 (zh) 2017-07-07
EP3004084A1 (fr) 2016-04-13
PE20160092A1 (es) 2016-03-03
TW201536776A (zh) 2015-10-01
JP2016520111A (ja) 2016-07-11
CU20150164A7 (es) 2016-05-30
US20160137647A1 (en) 2016-05-19
MA38637B1 (fr) 2018-04-30
CA2913960A1 (fr) 2014-12-11
AR096516A1 (es) 2016-01-13
ES2624996T3 (es) 2017-07-18
NI201500168A (es) 2016-09-29
BR112015029579A2 (pt) 2017-07-25
IL242794A0 (en) 2016-02-01
EA201501176A1 (ru) 2016-10-31
CL2015003476A1 (es) 2016-08-26
AU2014277072A1 (en) 2015-12-24
CN105408327A (zh) 2016-03-16
AP2015008896A0 (en) 2015-12-31
KR20160016815A (ko) 2016-02-15
TN2015000523A1 (en) 2017-04-06
PH12015502650A1 (en) 2016-03-07
UY35592A (es) 2014-12-31
MX2015016386A (es) 2016-04-13
WO2014195231A1 (fr) 2014-12-11
US9493472B2 (en) 2016-11-15
CR20150631A (es) 2016-01-12

Similar Documents

Publication Publication Date Title
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
TR201816379T4 (tr) DNA-PK inhibitörleri.
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
UA114087C2 (xx) Похідні піридину
EA201892147A1 (ru) Бициклические соединения
UY34811A (es) Compuestos y composiciones para inhibir la actividad de la abl1, abl2 y bcr-abl1
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA38365A1 (fr) Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
UA122324C2 (uk) Терапевтично активні сполуки і способи їх застосування
MX384420B (es) Cultivo, producción, procesamiento y uso de cannabis de especialidad.
CR20150066A (es) 2,3-benzodiacepinas
EA202191301A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
MX382899B (es) Composiciones y métodos que comprenden variantes de proteasa termolisina.
MA38247B1 (fr) Compositions pesticides et procédés associés
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
PH12014501176A1 (en) Anticoagulant reversal agents
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
CR20140128A (es) Inhibidores de la enzima activadora de nedd 8
IN2015DN00924A (fr)
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
CO2017003004A2 (es) Nuevas triazolo[4,5-d]pirimidinas
MA38925A1 (fr) Dérivés de phénylalanine substitués
MX360806B (es) Benzoxazinonas de carbamato.